Alder BioPharmaceuticals is now looking for a new chief executive, just as the company readies plans to file for FDA approval of its lead drug for migraine headaches.
Randy Schatzman (pictured above, right) is out as Alder’s (NASDAQ: ALDR) CEO, the Bothell, WA, company announced Tuesday after the markets closed. Schatzman also resigned from the company’s board of directors. In his place, Alder has appointed board member Paul Cleveland to serve as interim CEO. Cleveland will also keep his board seat. A spokesman for Alder said the company would not comment beyond the press release.
Though the executive change was… Read more »
UNDERWRITERS AND PARTNERS